Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Autor:	Brennen WN; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University, Baltimore, Maryland, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Pharmacology & Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA., Le Magnen C; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Urology, University Hospital Basel, Basel, Switzerland.; Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland., Karkampouna S; Urology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland., Anselmino N; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bock N; School of Biomedical Sciences at Translational Research Institute, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia.; Max Planck Queensland Centre for the Materials Science of Extracellular Matrices, Queensland University of Technology (QUT), Brisbane, QLD, Australia.; Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD, Australia., Choo N; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia., Clark AK; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia., Coleman IM; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Dolgos R; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Urology, University Hospital Basel, Basel, Switzerland.; Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland., Ferguson AM; Department for BioMedical Research, University of Bern, Bern, Switzerland.; Katharina Gaus Light Microscopy Facility, Mark Wainwright Analytical Centre, Division of Research and Enterprise, University of New South Wales, Sydney, NSW, Australia., Goode DL; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Krutihof-de Julio M; Urology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.; Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research, Translational Organoid Resource, University of Bern, Bern, Switzerland., Navone NM; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nelson PS; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA., O'Neill E; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Porter LH; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia., Ranasinghe W; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia.; Department of Surgery, Monash University, Melbourne, VIC, Australia.; Department of Urology, Monash Health, Melbourne, VIC, Australia.; Department of Urology, Austin Health, Melbourne, VIC, Australia., Sunada T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan., Williams ED; School of Biomedical Sciences at Translational Research Institute, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia.; Australian Prostate Cancer Research Centre-Queensland, Brisbane, QLD, Australia.; Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia., Butler LM; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia.; Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Corey E; Department of Urology, University of Washington, Seattle, Washington, USA., van Weerden WM; Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands., Taylor RA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Department of Physiology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia.; Cabrini Institute, Cabrini Health, Malvern, VIC, Australia.; Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia., Risbridger GP; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Cabrini Institute, Cabrini Health, Malvern, VIC, Australia.; Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia., Lawrence MG; Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Clayton, VIC, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Cabrini Institute, Cabrini Health, Malvern, VIC, Australia.; Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
Jazyk:	angličtina
Zdroj:	The Prostate [Prostate] 2024 May; Vol. 84 (7), pp. 623-635. Date of Electronic Publication: 2024 Mar 07.
DOI:	10.1002/pros.24682
Abstrakt:	Background: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect the diversity of disease seen in clinical practice. In response to this challenge, research laboratories around the world have been developing new patient-derived models of prostate cancer, including xenografts, organoids, and tumor explants. Methods: In May 2023, we held a workshop at the Monash University Prato Campus for researchers with expertise in establishing and using a variety of patient-derived models of prostate cancer. This review summarizes our collective ideas on how patient-derived models are currently being used, the common challenges, and future opportunities for maximizing their usefulness in prostate cancer research. Results: An increasing number of patient-derived models for prostate cancer are being developed. Despite their individual limitations and varying success rates, these models are valuable resources for exploring new concepts in prostate cancer biology and for preclinical testing of potential treatments. Here we focus on the need for larger collections of models that represent the changing treatment landscape of prostate cancer, robust readouts for preclinical testing, improved in vitro culture conditions, and integration of the tumor microenvironment. Additional priorities include ensuring model reproducibility, standardization, and replication, and streamlining the exchange of models and data sets among research groups. Conclusions: There are several opportunities to maximize the impact of patient-derived models on prostate cancer research. We must develop large, diverse and accessible cohorts of models and more sophisticated methods for emulating the intricacy of patient tumors. In this way, we can use the samples that are generously donated by patients to advance the outcomes of patients in the future. (© 2024 The Authors. The Prostate published by Wiley Periodicals LLC.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text